Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2020  |  Volume : 16  |  Issue : 3  |  Page : 699-700

A rare entity: Recurrent cisplatin-induced bradycardia

1 Department of Pediatrics, Mersin University Faculty of Medicine, Mersin, Turkey
2 Department of Pediatric Oncology, Mersin University Faculty of Medicine, Mersin, Turkey
3 Department of Pediatric Intensive Care Unit, Mersin University Faculty of Medicine, Mersin, Turkey

Date of Submission16-Jan-2018
Date of Decision23-Jul-2018
Date of Acceptance01-Aug-2018
Date of Web Publication08-Feb-2019

Correspondence Address:
Elvan Caglar Citak
Department of Pediatric Oncology, Mersin University Faculty of Medicine, Mersin
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_26_18

Rights and Permissions

How to cite this article:
Sagcan F, Citak EC, Karpuz D, Alakaya M. A rare entity: Recurrent cisplatin-induced bradycardia. J Can Res Ther 2020;16:699-700

How to cite this URL:
Sagcan F, Citak EC, Karpuz D, Alakaya M. A rare entity: Recurrent cisplatin-induced bradycardia. J Can Res Ther [serial online] 2020 [cited 2020 Aug 7];16:699-700. Available from: http://www.cancerjournal.net/text.asp?2020/16/3/699/263859


Cisplatin is commonly used in many chemotherapy protocols. Depending on the use of cisplatin, arrhythmia, myocarditis, pericarditis, diastolic disorders, cardiac ischemia, acute myocardial infarction, thromboembolic events, and chronic heart failure have been reported. Bradycardia is a rare side effect of cisplatin. According to the Food and Drug Administration reports, cisplatin-induced bradycardia accounted for 0.39% of all cisplatin side effects.[1]

A 17-year-old boy was diagnosed with Stage III nasopharyngeal carcinoma. Chemotherapy protocol consisting of intravenous cisplatin (75 mg/m2) was administered over 6 h on the 1st day of treatment; fluorouracil (1000 mg/m2) was given for 5-day continuous infusion.

Pre- and postcisplatin hydration contained magnesium sulfate, potassium chloride, and calcium gluconate, and there was also mannitol in the fluid during cisplatin infusion. Urine density was less than 1010 before infusion. As an antiemetic, granisetron was administered daily throughout the treatment. While receiving cisplatin, he was incidentally detected to have a heart rate of 41 bpm during routine vital parameter examination. There were no signs of parasympathetic hyperactivity, and the physical examination including blood pressure (125/80 mmHg) was within normal limits. Serum electrolytes were within normal limits. Electrocardiogram showed sinus bradycardia with heart rate of 34 bpm and QTc was 422 ms (normal value <440 ms) [Figure 1]. Echocardiography showed only patent foramen ovale. Since the patient was asymptomatic, he was observed with continuous cardiac monitoring. Minimum heart rate recorded was 38 bpm. The bradycardia that was detected in the patient recovered 30 min after the end of the cisplatin infusion without any intervention [Table 1]. In other days of treatment, bradycardia was not seen during fluorouracil and granisetron treatment. Recurrent bradycardia attacks were detected only during cisplatin infusion throughout the subsequent four cycles of chemotherapy.
Figure 1: Electrocardiogram with heart rate of 35 bpm during cisplatin infusion

Click here to view
Table 1: Characteristics of Bradycardia Episodes in Consecutive Chemotherapy Cycles

Click here to view

Cardiac toxicity is a well-known side effect of many antineoplastic drugs and most commonly seen with anthracyclines. Toxic effects ranging from myocardial damage to dysrhythmias in a wide spectrum has been described. Rhythm disorders that caused by antineoplastic drugs may occur during or shortly after administration with possible mechanisms such as direct effects of the drug on the heart, coronary artery spasm, electrolyte imbalance, and autonomic cardioneuropathy.[2] Dysrhythmias including bradycardia have rarely been defined by cisplatin infusion. The mechanism of cisplatin-induced bradycardia is presumed to be that the sinoatrial node effect that causes the disruption of the heart's electrical conduction system.[2],[3],[4]

Cisplatin is commonly associated with electrolyte imbalances such as hypokalemia, hypomagnesemia, hypophosphatemia, hypocalcemia, and hyponatremia, which cause dysrhythmias. Bradycardia has been reported to occur during or shortly after cisplatin infusion, without any abnormalities of serum electrolyte concentrations or blood pressure or other physical examination findings.[2],[3],[4],[5] In our patient, no electrolyte disturbance was detected during recurrent bradycardia attacks.

In most of the cases, bradycardia improved without any treatment as in our case. Bradycardia has been rarely reported to develop during each chemotherapy cycle treated with cisplatin like our case.[2],[5] Cisplatin-induced bradycardia is a rare condition and should be taken into account that it may develop during treatment.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that name and initial will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

 > References Top

Cisplatin and Bradycardia from FDA Reports. Available from: http://www.ehealthme.com/ds/cisplatin/bradycardia. [Last accessed on 2018 Dec 12].  Back to cited text no. 1
Cabuk D, Demir M, Yaylaci S, Vatan M, Tamer A. Recurrent bradycardia episodes induced by cisplatin infusion. Sakaryamj 2013;3:218-20.  Back to cited text no. 2
Kucharz J, Michalowska-Kaczmarczyk A, Zygulska AL, Wojtak J, Pawlik W, Herman RM, et al. Bradycardia as a rare symptom of cisplatin cardiotoxicity: A case report. Oncol Lett 2016;11:2297-9.  Back to cited text no. 3
Darling HS. Cisplatin induced bradycardia. Int J Cardiol 2015;182:304-6.  Back to cited text no. 4
Altundaǧ O, Celik I, Kars A. Recurrent asymptomatic bradycardia episodes after cisplatin infusion. Ann Pharmacother 2001;35:641-2.  Back to cited text no. 5


  [Figure 1]

  [Table 1]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  >Article Figures>Article Tables
  In this article

 Article Access Statistics
    PDF Downloaded259    
    Comments [Add]    

Recommend this journal